Additionally, a global Phase III trial on osimertinib in treatment-naïve EGFR-mutant NSCLC patients reported PFS of 21.4 months and 14.4 months for exon 19 deletion and L858R mutation patients, respectively, indicating a trend toward superior PFS in the exon 19 deletion group compared to the L858R group (12). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.